Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07618026 · ClinicalTrials.gov registry record · NA
Establishing Effects of Bacillus Clausii Probiotic Consumption on Gastrointestinal Health and Inflammation
A NA study, sponsored by Colorado State University.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
NCT07618026: Completed NA study, sponsored by Colorado State University.
NCT07618026 is a NA study that has completed, run by Colorado State University. The registered enrollment target is 55 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07618026, a NA study, has completed, sponsored by Colorado State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
Study Summary
The study is a randomized, double-blind, crossover, placebo-controlled clinical intervention trial to test the effects of a commercial Bacillus (Shouchella) clausii probiotic compared to a placebo on gastrointestinal symptoms.
Primary Outcome
For each arm adverse event forms were tracked and the total rate of adverse events was calculated
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Bacillus (Shouchella) clausii CSI08
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2024-03-28 |
| Est. Completion | 2025-03-31 |
| Phase | NA |
What the finished NCT07618026 record still lists
NCT07618026 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07618026 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07618026 about?
NCT07618026 is a clinical study titled "Establishing Effects of Bacillus Clausii Probiotic Consumption on Gastrointestinal Health and Inflammation". The study is a randomized, double-blind, crossover, placebo-controlled clinical intervention trial to test the effects of a commercial Bacillus (Shouchella) clausii probiotic compared to a placebo on gastrointestinal symptoms.
What is the current status of trial NCT07618026?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2024-03-28. Estimated completion is 2025-03-31.
What interventions are being tested in trial NCT07618026?
The interventions under investigation include: Placebo (OTHER), Bacillus (Shouchella) clausii CSI08 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07618026?
This trial is sponsored by Colorado State University, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07618026's enrollment target sits among peer trials
55 1264th of 2000 higher than 733 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI